ABIONYX Pharma: €3.5 Million in Cash Reserves and a Major Bet Against Sepsis
ABIONYX Pharma announces its annual results for 2025 and outlines its strategic directions focused on actively preparing for the next clinical phase in sepsis, as well as continuing industrial bioproduction activities. The company benefits from extended financial visibility until the end of June 2027 thanks to funding received under the France 2030 initiative.
Strategic Deployment of Bioproduct through Compassionate Access Authorizations
ABIONYX Pharma has strategically chosen to provide its bioproduct free of charge under Compassionate Access Authorizations (CAA). This approach aims to broaden patient access to innovative treatments while enhancing the clinical experience and medical validation of the product under real-world usage conditions. The group is actively pursuing the optimization of industrial bioproduction since being named a winner of the i-Demo tender under the France 2030 plan. The clinical value of the bioproduct has been strengthened through a partnership with the IHU Sepsis.
Financial Overview and Government Support
ABIONYX Pharma has a cash reserve of €3.5 million as of December 31, 2025. The company was a recipient of the 'i-Demo' project call under the France 2030 plan and received €8.7 million in state support to fight sepsis, with €6.5 million still to be received. Based on its current cash reserves, independent of this funding, the company maintains extended financial visibility until the end of 2026, which will extend to the end of June 2027 upon receipt of the remaining France 2030 funds.
